Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

Figure 11: Summary of Thalidomide Efficacy for CR and PPR 25%


Newly diagnosed/previously untreated multiple myeloma

Advanced/refractory/resistant multiple myeloma

Thalidomide only

CR 16-25%

CR 2-9%

Thalidomide plus dexamethasone

CR 8-16%

CR 0-13%

Thalidomide plus other agents

Not appropriate to summarize

Not appropriate to summarize

Thalidomide pre- or post-SCT

Not appropriate to summarize

a. Reports of PPR >50% can be misleading.

Return to Document

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care